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Abstract
Introduction Chronic infection with Tropheryma whipplei,
known as Whipple’s disease (WD), classically affects the
gastrointestinal tract, but any organ system may be affec-
ted, and isolated manifestations occur. Reliable diagnosis
based on a combination of periodic acid–Schiff (PAS)
staining, T. whipplei-specific immunohistochemistry
(IHC), and polymerase chain reaction (PCR) from duode-
nal biopsies may be challenging in cases without classical
gastrointestinal infection, so the need for additional diag-
nostic materials is urgent.
Objective Our objective was to evaluate additional diag-
nostic possibilities for WD.
Methods We analyzed samples from 20 patients with WD
and 18 control subjects in a prospective observational pilot
study. In addition to WD diagnosis by PAS staining, T.
whipplei-specific IHC and PCR of duodenal or extra
intestinal tissues, whole EDTA blood, peripheral blood
mononuclear cells (PBMCs) and PBMC fractions enriched
with or depleted of cluster of differentiation (CD)-14? cells
were examined using T. whipplei rpoB gene PCR.
Results Tropheryma whipplei DNA was detected in 35 of
60 (58.3%) preparations from 16 of 20 patients with WD,
most of whom lacked gastrointestinal signs and charac-
teristic PAS-positive duodenal macrophages.
Conclusion This study provides evidence for the potential
suitability of blood, particularly PBMCs, as material to
assist in the diagnosis of WD via rpoB gene real-time PCR.
Thus, PCR from blood preparations can be helpful for
diagnostic decision making in atypical cases of WD.
Key Points
RpoB gene polymerase chain reaction (PCR) can be
an additional tool to assist in the diagnosis of
Whipple’s disease.
RpoB gene PCR from blood fractions, especially
peripheral blood mononuclear cells (PBMCs),
enables the surveillance of treatment efficacy and
thus appears to have advantages over
immunohistochemistry (IHC) and periodic acid–
Schiff (PAS) staining.
1 Introduction
The rare systemic chronic infection with Tropheryma
whipplei [1], known as Whipple’s disease (WD), has an
estimated incidence of 1:1,000,000 [2, 3]. The classical
clinical features of WD are polyarthritis, diarrhea, weight
loss, and fever [2]. However, as T. whipplei can affect
almost any organ, WD cases with non-classical symptoms
can be frequent. The standard for diagnosis of WD is
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usually based on periodic acid–Schiff (PAS) staining of
macrophages in the duodenal lamina propria [2] and should
be confirmed by an independent specific method such as
polymerase chain reaction (PCR) [4–7]. However, no
systematic data are available concerning the sensitivity or
specificity of these routine tests, and no ‘‘gold standard’’ is
available. Improved diagnostic methods and clinical
awareness means that non-classical WD, often associated
with isolated infection in the joints, heart valves, or central
nervous system [8–10], is increasingly being recognized
[10, 11]. In cases without the gastrointestinal involvement
typical of classical WD (i.e., in the absence of gastroin-
testinal symptoms and positive PAS staining from the
duodenum), confident diagnosis depends on methods that
are not routinely available (such as T. whipplei-specific
immunohistochemistry [IHC]) or analysis of additional
biopsies of the affected organ or heart valve. It appears that
PCR and IHC of duodenal tissue can identify more patients
and has similar WD detection rates in cases without PAS-
positive duodenal macrophages [4, 12]. However, the
sensitivity and specificity of PCR and IHC has not been
evaluated systematically. Therefore, an additional diag-
nostic tool that is less invasive would be helpful in
inconclusive cases.
Relman et al. [7] proposed the detection of T. whipplei
DNA in blood as a promising alternative. However,
detection rates using PCR from the whole blood of patients
with active WD targeting repeated sequences of T. whipplei
[4] or from peripheral blood mononuclear cells (PBMC)
targeting T. whipplei-specific 16S rDNA [13] have so far
been low. These low rates may have been due to the genes
targeted for detection, DNA being prepared by methods
only optimized for the isolation of eukaryotic DNA, or
insufficient amount of material (e.g., 200 ll of fluid in
Fenollar et al. [4]). Here, we aimed to assess the value of a
previously validated more sensitive rpoB gene PCR [14]
for the detection of T. whipplei DNA in whole blood and
PBMCs following DNA isolation optimized for mycobac-
teria [14]. In addition, given that Raoult et al. [15] reported
the immunodetection of T. whipplei in circulating mono-
cytes, we evaluated whether the enrichment of cluster of
differentiation (CD)-14? monocytes is advantageous for
the detection of T. whipplei DNA.
Therefore, we conducted a prospective observational
pilot study to evaluate the relevance of rpoB gene real-time
PCR [14] from EDTA blood, purified PBMCs, and PBMC
fractions enriched with or depleted of CD14? monocytes in
patients with chronic T. whipplei infection to assist in the
diagnosis of WD.
2 Material and Methods
2.1 Patients
We included 32 patients with symptoms compatible with
WD (e.g., treatment-resistant seronegative rheumatoid
arthritis, gastrointestinal symptoms) and 18 control sub-
jects with other indications for control gastroscopy from
May 2014 until May 2017 (Fig. 1). Cases were identified as
previously described [12], with at least two positive results
from routine PAS staining, T. whipplei-specific IHC [16]
Fig. 1 Details of the analysed cohort with excluded cases, confirmed Whipple disease, and control subjects. WD Whipple’s disease, PAS
periodic acid–Schiff, PCR polymerase chain reaction, TW IHC T. whipplei-specific immunohistochemistry
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from duodenal or extra intestinal tissues (e.g., lymph node,
cardiac valve), or rpoB gene real-time PCR [14] from tis-
sues or fluids (e.g., cerebrospinal fluid, synovial fluid).
Every positive rpoB–PCR result was confirmed by con-
ventional T. whipplei-specific 16S rRNA amplification
based on a slightly modified protocol published by von
Herbay et al. [17], using primers TPU5 [18] and whip1 and
whip2 [17], subsequent gene sequencing, and comparison
with all currently available sequences from public data-
bases (EMBL and GenBank) [14]. Patients with charac-
teristic PAS-positive macrophages in duodenal samples
and gastrointestinal signs were defined as having classical
WD. We recruited 18 people with indications for gas-
troscopy but without positive diagnostic tests for T. whip-
plei as control subjects (Table 1). All control subjects had
received a diagnosis other than WD and responded to
appropriate treatment; no further indication of WD was
found during follow-up (Table 1). A total of 12 patients
were excluded because they had only a single positive test,
meaning the WD diagnosis was doubtful, or they had
received treatment for [ 4 weeks. Among the 20 patients
with confirmed WD enrolled in this study (see Table 1 and
Fig. 1 for details), 16 were previously untreated and four
(patients 12–14 and 17) had received antibiotic treatment
up to 14 days before analysis. For six patients (patients 1,
3, 5, 10, 13, and 17), follow-up examination was performed
3 months after initiation of antibiotic treatment (see
Table 1 for details). All patients and control subjects gave
informed consent, and one patient with classical WD (pa-
tient 5, see Table 1) is described in a published case report
[19].
2.2 Sampling of Blood, Isolation of Peripheral Blood
Mononuclear Cells (PBMCs) and Sorting
of Cluster of Differentiation (CD)-141
and CD142 PBMCs
Blood samples were stored at room temperature and pro-
cessed within 24 h after sampling. Peripheral blood was
collected in EDTA tubes (Vacutainer, BD Biosciences) for
whole blood analysis, and PBMCs were isolated from
heparinized blood as previously described [20]. CD14?
monocytes were isolated from PBMCs using CD14
MicroBeads (1:10), LS columns, and a MidiMACS magnet
according to the manufacturer’s protocol (Miltenyi Biotec,
Bergisch Gladbach, Germany) [21]. The throughputs of the
CD14 MACS sort depleted of CD14? monocytes served as
CD14- fractions of PBMCs. Since we hypothesized that T.
whipplei more reliably persist in CD14? monocytes, the
fraction depleted of CD14? cells was intended to serve as a
kind of negative control with lower detection rates. CD14?
purity of the CD14? fractions was estimated using flow
cytometry with a CD14 (61D3) antibody from eBiocience
(Frankfurt, Germany). While CD14? fractions of patients
with WD (n = 16) and of control subjects (n = 11)
revealed a similar mean percentage of total CD14? (WD:
91.03 ± 7.15%; controls: 96.26 ± 5.67%), CD14high were
significantly lower (WD: 77.75 ± 16.08%; controls:
94.68 ± 7.65%; p = 0.019) and CD14low were signifi-
cantly higher in patients with WD than in control subjects
(WD: 11.46 ± 9.10%; controls: 1.59 ± 2.04%;
p = 0.003). CD14- fractions were analyzed for only five
patients with WD and revealed a contamination of
8.56 ± 4.64% of CD14low and 0.70 ± 0.44% of CD14high
monocytes.
2.3 DNA Extraction
Total genomic DNA was extracted from 1 ml frozen
EDTA blood or, corresponding to the cell count of 1 ml
blood, from 2 9 106 cells isolated from heparinized blood
(PBMCs and cell fractions enriched with or depleted of
CD14? monocytes, respectively). DNA was isolated using
the AMPLICOR Respiratory Specimen Preparation Kit
(Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s instructions, with the following modi-
fication for EDTA blood: twice the recommended volume
of ‘‘respiratory specimen wash solution’’ was used in a
washing step. For all preparations, elution volumes were
identical.
To reduce PCR-inhibitory components in DNA extrac-
ted from EDTA blood, an additional purification included
column-based enrichment via QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany).
2.4 RpoB Gene Real-Time Polymerase Chain
Reaction (PCR) Assay
Total genomic DNA was analyzed for T. whipplei DNA by
validated rpoB gene real-time PCR as previously described
[14]. Primers TwrpoB-F4: CTCGGTGTTGATGTT-
GATCCAA and TwrpoB-R: GCACCGCAACCTCGGA-
GAAA [22] were used to amplify a 109-bp segment of the
T. whipplei rpoB gene from 5 ll of isolated DNA. Real-
time detection of the amplicons was achieved using
LightCycler hybridization probes TwrpoB-HP1:
ACGAGGTCGGATATTATCGC-[FL] (50–30) and Twr-
poB-HP2: [Red 640]-ACAATTCGTTATCTCGCGGCC
(50–30) [14]. Oligonucleotides were synthesized using TIB
MOLBIOL (Berlin, Germany), and real-time PCR was
performed in a LightCycler instrument, version 2.0 (Roche
Diagnostics) as previously described [14].
As standard curve, extracted DNA from a serial dilution
of T. whipplei strain Twist ATCC VR-1528 was used, as
previously described [14]. The sensitivity of the real-time
PCR assay was determined at 17.4 microorganisms per
T. Whipplei in Peripheral Blood Mononuclear Cells 461
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5-ll suspension (cycle threshold [CT] 38.0 ± 0.5). At
higher dilutions, the positive results were not consistent in
triplicate samples. A high (CT 31.0) and a low (CT 33.0)
positive control were included in every PCR run to ensure
sensitivity of the actual experiment. To assure optimal
amplification in a specific blood sample, an inhibition
control at the concentration of the low positive control was
also included.
2.5 Histology and Immunohistochemistry
Tissue specimens were fixed in formalin and embedded in
paraffin, and thin sections were subjected to routine PAS
staining. Immunostaining was performed as previously
described [16, 23] with rabbit-anti-T. whipplei [16], visu-
alized by donkey-anti-rabbit Biotin (Dianova, Hamburg,
Germany), Streptavidin-alkaline phosphatase and Fast red
(both DakoCytomation, Glostrup, Denmark). Nuclei were
counterstained with Meyer’s Hematoxilin
(DakoCytomation).
3 Results
Among the 20 patients with WD, only six experienced
typical clinical symptoms and revealed characteristic PAS-
positive macrophages in the duodenal lamina propria and
were thus defined as having classical WD (Table 1, Fig. 1).
One further patient revealed atypical PAS-positive cells in
the duodenal submucosa (Table 1, patient 14). Although
the specificity of the PAS staining of duodenal biopsies as
the classical diagnostic method for WD for our cohort was
100%, the sensitivity (38.9%) and negative predictive
value (62.1%) was very low. T. whipplei-specific IHC of
the duodenum and rpoB gene PCR from duodenal tissue
revealed positive results for all included patients with WD
and none of the control subjects (Table 1). Among 11
patients with atypical WD, nine presented with only a faint
positive T. whipplei-specific IHC within the duodenal
submucosa (Table 1, Fig. 2a, b). Two patients were ini-
tially identified via histological analysis of lymph nodes
excised to exclude malignant disease (Fig. 2c, d), and two
patients with isolated T. whipplei-induced endocarditis
were diagnosed via analysis of cardiac valves (Table 1,
Fig. 2e, f). In addition, PCR from cerebrospinal fluid was
positive for 8 of 15 patients (Table 1).
The overall detection rate for T. whipplei in blood
samples was 35 of 60 samples and evidenced bacterial
DNA in 16 of 20 patients (EDTA: 7/17 patients tested;
PBMC: 11/18; enriched for CD14?: 9/15; and depleted of
CD14?: 8/10) (Table 1). Upon analysis of the different
blood fractions, rpoB gene PCR revealed T. whipplei DNA
in EDTA blood of 7 of 17 patients with WD (sensitivity ofT
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41.2%). The detection rate improved to 61.1% sensitivity
when investigating PBMCs (Table 1). Similar results were
obtained investigating CD14? monocytes. However, the
highest sensitivity for T. whipplei DNA (80%) and the most
reliable negative predictive value (77.8%) was found in the
CD14?-depleted cell fraction (Table 1), originally inclu-
ded for some patients as a negative control.
An interim analysis after inclusion of 15 patients with
WD indicated that enrichment of CD14? cells did not
improve the T. whipplei detection rate compared with
PBMCs, as initially hypothesized. Despite the good results
with the CD14?-depleted PBMCs, we chose PBMCs to
assist in WD diagnosis for subsequent patients, resulting in
fewer specimens per patient. This decision was based on
the lowest CT values for rpoB gene PCR analysing
PBMCs, indicating a more reliable level of T. whipplei
DNA. While mean CT values from EDTA blood samples
were as high as 38.02 ± 2.02, the analysis of PBMCs
resulted in significantly lower mean CT values of
32.75 ± 2.33 (p = 0.0016; Mann–Whitney test). CT values
Fig. 2 Immunohistochemical
diagnosis of atypical Whipple’s
disease (WD) from duodenal
biopsy (a, b), lymph node (c, d),
and heart valve (e, f). Panels
demonstrate exemplary
presentations of periodic acid–
Schiff (PAS) staining in purple
(a, c, e) and Tropheryma
whipplei-specific
immunohistochemistry in bright
red (b, d, f): a conventional
PAS staining of the duodenum
reveals no hint of WD; b T.
whipplei-specific
immunohistochemistry
identifies numerous infected
cells within the duodenal
submucosa; c positive PAS
staining in a lymph node with
lymphangiectasia (positive
areas are marked by
arrowheads); d corresponding
clearly positive T. whipplei-
specific immunohistochemistry;
e inflammatory infiltrate with
PAS-positive inclusions in a
heart valve (positive areas are
marked by arrowheads); f T.
whipplei-specific
immunohistochemistry
demonstrates infection with T.
whipplei; magnification for all
pictures 9100
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of PBMCs enriched for CD14? (35.22 ± 2.65) and
PBMCs depleted of CD14? (34.76 ± 3.68) were also
increased compared with the whole PBMC fraction. Since
CT values [ 38 are at the limit of rpoB gene PCR sensi-
tivity [14], high CT values as observed for EDTA blood
and CD14?-depleted and enriched PBMC fractions may
produce inconsistent results. In addition, sorting for CD14
is not routine in laboratories, bears a greater risk of con-
tamination, and is associated with additional effort and
costs.
Within 14 days of antibiotic treatment, T. whipplei DNA
was still detected by rpoB gene PCR (Table 1, patients
12–14, and 17). However, at the 3-month follow-up
examination, none of the six specimens tested revealed a
positive PCR, indicating a rapid reduction in bacterial
DNA in vivo (patients 1, 3, 5, 10, 13, and 17; data not
shown). In addition, no T. whipplei DNA was detected in
any of the 44 blood preparations (EDTA blood, unsorted
PBMCs, or PBMCs enriched with or depleted of CD14?)
from the 18 control subjects. Therefore, although the sen-
sitivity of the assay depends on the material used for DNA
isolation, rpoB gene PCR of blood samples revealed a
specificity and a positive predictive value (PPV) of 100%
each in our cohort, confirming this method as a supporting
tool in WD diagnosis.
4 Discussion
This study has shown the potential suitability of blood and
particularly PBMCs as material for rpoB gene real-time
PCR to assist in the diagnosis of WD. Awareness of the
possibility of isolated WD, atypical—possibly early—WD
without gastrointestinal symptoms, and PAS-positive duo-
denum is increasing [4, 9, 10, 12]. Indeed, specific IHC can
confirm T. whipplei infection in tissues even in the absence
of PAS staining (Fig. 2) [12], but this method is only
accessible at specialized centers as the antibodies are not
commercialized. PCR from duodenal specimens is also
highly indicative of WD [4, 12]; however, healthy luminal
carriage of T. whipplei without invasive infection may also
result in positive PCR [4]. In cases with no gastrointestinal
infection, sampling of affected tissue may be virtually
impossible. Consequently, alternative diagnostic materials
to assure diagnosis by T. whipplei-specific PCR from
multiple physiologically sterile sites are urgently needed.
We demonstrated that detection of T. whipplei DNA in
whole blood and PBMCs by rpoB gene PCR seems to be
highly indicative of WD, even in the absence of intestinal
infection and duodenal PAS staining. In our cohort, PAS
staining of duodenal biopsies identified only 38.9% of
patients, whereas the combined analysis of PBMCs and
PBMC fractions enriched with or depleted of CD14?
monocytes enabled detection of bacterial DNA in 16 of 20
patients with confirmed WD (80%). The feasibility of PCR
with PBMCs from patients following short-term treatment
was demonstrated by positive results in four patients with
WD (two with isolated T. whipplei-induced endocarditis)
who received appropriate antibiotic treatment for up to
2 weeks prior to blood analysis.
PCR from PBMCs identified more patients, possibly
indicating a higher bacterial load, and revealed an enrich-
ment of T. whipplei DNA, indicated by lower CT values as
compared with PCR from EDTA blood, and thus seems
superior. However, detection of T. whipplei DNA did not
increase after enrichment of CD14? monocytes, and T.
whipplei DNA was also detected in PBMC depleted of
CD14? monocytes. Even though the PBMC fraction
depleted for CD14? cells exhibited the best diagnostic
results in our cohort, we recommend PBMCs as the most
suitable material to assist in the diagnosis of WD. PBMCs
enabled a higher detection rate at lower CT values of PCR
compared with EDTA blood, and the depletion of CD14?
monocytes necessitates an intensive work-up of the mate-
rial, which carries a greater risk of contamination. In
addition, CD14? depletion might be difficult to introduce
into routine diagnostic laboratories.
Obvious advantages of using PBMCs to assist in the
diagnosis of WD include the simple accessibility of blood,
the feasibility for outpatients, and the ability to standardize
sampling and cell numbers for semi-quantitative PCR
results. The rpoB real-time PCR sensitivity was determined
for approximately 17 target organisms per 5 ll of T.
whipplei culture used for DNA extraction (3480 organisms/
ml) [14]. Although the rpoB real-time PCR on PBMCs has
not yet been validated, we have already found that 2 9 106
PBMC—a comparatively low number—enabled the
detection of T. whipplei. On the basis of our experience,
2 9 106 cells correspond to the average amount of PBMCs
in 1 ml of peripheral blood of healthy donors. Thus, min-
imal blood is needed for T. whipplei screening, which is an
advantage for patients with diminished health. Another
benefit of rpoB gene PCR from PBMCs could be the rapid
clearance of T. whipplei DNA after initiation of treatment,
which—unlike PAS and IHC of duodenal specimens—may
allow monitoring of treatment efficacy or possibly early
detection of relapse. The lack of benefit from enriching
CD14? monocytes for detection of T. whipplei DNA hints
at a small proportion of infected monocytes only and
suggests that T. whipplei are not necessarily only associ-
ated with classical CD14high monocytes, as previously
presumed, but also with other cells. Classical CD14high
monocytes have been demonstrated to eliminate T. whip-
plei in vitro [24]; thus, T. whipplei DNA might have been
degraded more effectively in the PBMC fractions enriched
for CD14? monocytes. In contrast, the persistence of T.
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whipplei in monocytes is enabled by interleukin (IL)-16
and has been demonstrated to be associated with an
upregulation of CD16 [24]. CD16 is only expressed on
non-classical CD14low monocytes, which appear to be
elevated during acute infection [25]. The percentage of
CD14high monocytes in the CD14? monocyte fractions of
patients with WD was significantly lower as compared
with controls (77.75 % in WD patients versus 94.68% in
controls). However, non-classical CD14low monocytes
were significantly enhanced in the CD14? fraction of
patients with WD; when they were included in the analysis,
the purity of the CD14? fractions was similar for patients
and controls. The non-classical CD14low monocytes in the
untreated patients with WD included in our cohort might be
activated by the pathogen itself or by enhanced
lipopolysaccharides in the serum [26]. Thus, the high
percentage of CD14low monocytes in patients with WD
might be more difficult to access for the antibodies used for
depletion, resulting in contamination of the CD14-depleted
fraction with CD14low non-classical monocytes that might
be preferentially loaded with T. whipplei.
As classical CD14high monocytes and dendritic cells
were both removed from the PBMC fraction by depleting
CD14? cells, T. whipplei-positive cells are potentially
lymphocytes [27], CD16?CD14low non-classical mono-
cytes [24], or basophilic granulocytes. The variable posi-
tive results in different cell preparations for some patients
possibly indicates day-to-day variability in blood samples
or a low level of infected cells in the preparations.
The rpoB gene PCR recognized T. whipplei DNA in
PBMCs and enriched CD14? monocytes, respectively,
from two patients with T. whipplei-induced endocarditis
(Table 1, patients 12 and 17, diagnosed from excised heart
valve). One additional patient with endocarditis revealed
positive PCR results from PBMCs but was excluded
because heart valve replacement was not conducted,
meaning a second diagnostic finding to confirm WD was
not possible (see Fig. 1). Thus, this study indicates rpoB
gene PCR for the detection of T. whipplei DNA in isolated
PBMCs is a promising non-invasive material for decision
making in the diagnosis of WD, especially for atypical WD
when sampling of infected tissue is challenging (e.g., heart
valves).
Further studies to determine diagnostic benefits should
include more patients with isolated T. whipplei endo-
carditis, healthy patients with T. whipplei in stool samples,
and recurrent testing of blood samples and greater cell
numbers to determine the intraindividual variability of the
results. Importantly, identification of cell populations
associated with T. whipplei is of particular interest to
understand the pathways of the pathogen in the human
body. Until further studies evaluate these issues, this
approach should be restricted to specialized laboratories for
inconclusive cases.
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